MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Akcijų sąrašas・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

37.17 1.53

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

35.83

Max

37.18

Pagrindiniai rodikliai
By Trading Economics
Pajamos	7.3M -123M
Pardavimai	3.7M 3.9M
Pelnas, tenkantis vienai akcijai	-1.29
Pelno marža	-3,161.261
Darbuotojai	594
EBITDA	20M -122M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+140.63% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-901M 3.6B
Ankstesnė atidarymo kaina	35.64
Ankstesnė uždarymo kaina	37.17

Naujienos nuotaikos

By Acuity

50%

166 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

30.39 / 33.46 Palaikymas ir pasipriešinimas

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-02 17:11; UTC

Pagrindinės rinkos jėgos

Svarbiausios naujienos

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2026-04-02 17:10; UTC

Svarbiausios naujienos

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

2026-04-03 00:00; UTC

Svarbiausios naujienos

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2026-04-02 23:47; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2026-04-02 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2026-04-02 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2026-04-02 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2026-04-02 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2026-04-02 21:01; UTC

Svarbiausios naujienos

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2026-04-02 20:59; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks and Boyu Capital Finalize China JV

2026-04-02 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-02 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-02 20:41; UTC

Uždarbis

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2026-04-02 20:32; UTC

Rinkos pokalbiai

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2026-04-02 20:30; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026-04-02 20:09; UTC

Rinkos pokalbiai

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2026-04-02 20:01; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026-04-02 19:46; UTC

Rinkos pokalbiai

Is Oil the New GameStop? -- Market Talk

2026-04-02 19:35; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2026-04-02 19:29; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026-04-02 19:24; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2026-04-02 19:20; UTC

Rinkos pokalbiai

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2026-04-02 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2026-04-02 19:00; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific: Agreement Reached With American Train Dispatchers Association

2026-04-02 18:24; UTC

Įsigijimai, susijungimai, perėmimai

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2026-04-02 17:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2026-04-02 17:32; UTC

Svarbiausios naujienos

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2026-04-02 17:26; UTC

Uždarbis

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2026-04-02 17:17; UTC

Rinkos pokalbiai

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2026-04-02 17:09; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

140.63% į viršų

12 mėnesių prognozė

Vidutinis 88 USD 140.63%

Aukščiausias 97 USD

Žemiausias 67 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Crinetics Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

166 / 349 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.